182 related articles for article (PubMed ID: 24314222)
1. [Efficacy and safety of rh-endostatin combined with docetaxel in second-line or intolerant toxicity for first-line treatment in patients with advanced non-small cell lung cancer].
Wang J; Li K; Sun T; Zhang MJ; Li WL; Yao Q; Liu W; Ding CM; He ZY; Mao WD; Wang HM; Zhang Y; Zhou XL
Zhonghua Zhong Liu Za Zhi; 2013 Aug; 35(8):618-22. PubMed ID: 24314222
[TBL] [Abstract][Full Text] [Related]
2. [Efficacy of endostar combined with chemotherapy in multi-cycle treatment of patients with advanced non-small cell lung cancer].
Li N; Jin ZL; Liu ZJ; Wang J; Li K
Zhonghua Zhong Liu Za Zhi; 2011 Dec; 33(12):937-42. PubMed ID: 22340106
[TBL] [Abstract][Full Text] [Related]
3. [A multicenter, randomized, double-blind, placebo-controlled safety study to evaluate the clinical effects and quality of life of paclitaxel-carboplatin (PC) alone or combined with endostar for advanced non-small cell lung cancer (NSCLC)].
Han BH; Xiu QY; Wang HM; Shen J; Gu AQ; Luo Y; Bai CX; Guo SL; Liu WC; Zhuang ZX; Zhang Y; Zhao YZ; Jiang LY; Shi CL; Jin B; Zhou JY; Jin XQ
Zhonghua Zhong Liu Za Zhi; 2011 Nov; 33(11):854-9. PubMed ID: 22335953
[TBL] [Abstract][Full Text] [Related]
4. Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial.
Garon EB; Ciuleanu TE; Arrieta O; Prabhash K; Syrigos KN; Goksel T; Park K; Gorbunova V; Kowalyszyn RD; Pikiel J; Czyzewicz G; Orlov SV; Lewanski CR; Thomas M; Bidoli P; Dakhil S; Gans S; Kim JH; Grigorescu A; Karaseva N; Reck M; Cappuzzo F; Alexandris E; Sashegyi A; Yurasov S; Pérol M
Lancet; 2014 Aug; 384(9944):665-73. PubMed ID: 24933332
[TBL] [Abstract][Full Text] [Related]
5. A multicenter phase II study of docetaxel, oxaliplatin, and bevacizumab in first-line therapy for unresectable locally advanced or metastatic non-squamous cell histology non-small-cell lung cancer (NSCLC).
Raez LE; Santos ES; Webb RT; Wade J; Brito RA; Karr M; Kennah A; Childs BH
Cancer Chemother Pharmacol; 2013 Nov; 72(5):1103-10. PubMed ID: 24057043
[TBL] [Abstract][Full Text] [Related]
6. [Comparison of the efficacy of nedaplatin combined with docetaxel and docetaxel alone as a second line treatment for advanced non-small cell lung cancer].
Gu LP; Shen SP; Chen ZW
Zhonghua Zhong Liu Za Zhi; 2010 Dec; 32(12):939-42. PubMed ID: 21223805
[TBL] [Abstract][Full Text] [Related]
7. A randomized, double-blind, phase II study of ramucirumab plus docetaxel vs placebo plus docetaxel in Japanese patients with stage IV non-small cell lung cancer after disease progression on platinum-based therapy.
Yoh K; Hosomi Y; Kasahara K; Yamada K; Takahashi T; Yamamoto N; Nishio M; Ohe Y; Koue T; Nakamura T; Enatsu S; Lee P; Ferry D; Tamura T; Nakagawa K
Lung Cancer; 2016 Sep; 99():186-93. PubMed ID: 27565938
[TBL] [Abstract][Full Text] [Related]
8. [Phase I/II clinical trial of weekly administration of docetaxel plus cisplatin for advanced non-small cell lung cancer].
Li JL; Zhang XR; Liu JW; Chen ZY; Lin YC; Wang YD; Chen Q; Nan KJ; Song SP; Han FC; Zhu YZ; Li LY; Zheng YH; Chu DT
Zhonghua Zhong Liu Za Zhi; 2006 Apr; 28(4):309-12. PubMed ID: 16875636
[TBL] [Abstract][Full Text] [Related]
9. The Evaluation of Durative Transfusion of Endostar Combined with Chemotherapy in Patients with Advanced Non-Small Cell Lung Cancer.
Li X; Gu G; Soliman F; Sanders AJ; Wang X; Liu C
Chemotherapy; 2018; 63(4):214-219. PubMed ID: 30347389
[TBL] [Abstract][Full Text] [Related]
10. Phase III trial comparing vinflunine with docetaxel in second-line advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy.
Krzakowski M; Ramlau R; Jassem J; Szczesna A; Zatloukal P; Von Pawel J; Sun X; Bennouna J; Santoro A; Biesma B; Delgado FM; Salhi Y; Vaissiere N; Hansen O; Tan EH; Quoix E; Garrido P; Douillard JY
J Clin Oncol; 2010 May; 28(13):2167-73. PubMed ID: 20351334
[TBL] [Abstract][Full Text] [Related]
11. [A randomized phase II trial of docetaxel and doxorubicin in treatment for patients with non-small-cell lung cancer who have failed previous platinum-based chemotherapy].
Wang ZP; Sun Y; Zhang XR; Zhang MH; Wang XW; Yu XJ; Nan KJ; Li EX; Liu JW; Gao YJ; Guan XQ; Song SP; Sheng LJ; Wang DL; Wang ZX
Zhonghua Zhong Liu Za Zhi; 2008 Jun; 30(6):465-8. PubMed ID: 19024525
[TBL] [Abstract][Full Text] [Related]
12. A randomized phase II study of a combination of docetaxel and S-1 versus docetaxel monotherapy in patients with non-small cell lung cancer previously treated with platinum-based chemotherapy: results of Okayama Lung Cancer Study Group (OLCSG) Trial 0503.
Segawa Y; Kiura K; Hotta K; Takigawa N; Tabata M; Matsuo K; Yoshioka H; Hayashi H; Kawai H; Aoe K; Maeda T; Ueoka H; Tanimoto M
J Thorac Oncol; 2010 Sep; 5(9):1430-4. PubMed ID: 20651615
[TBL] [Abstract][Full Text] [Related]
13. [Efficacy and prognostic factors of 178 advanced non-small lung cancer patients undergoing different second-line chemotherapeutic regimens].
Kong Q; Wang XY; Jiang RC; Ba Y; Li K
Zhonghua Zhong Liu Za Zhi; 2016 Apr; 38(4):294-9. PubMed ID: 27087377
[TBL] [Abstract][Full Text] [Related]
14. Randomised phase II trial of 4 dose levels of single agent docetaxel in performance status (PS) 2 patients with advanced non-small cell lung cancer (NSCLC): DOC PS2 trial. Manchester lung cancer group.
Califano R; Griffiths R; Lorigan P; Ashcroft L; Taylor P; Burt P; Lee L; Chittalia A; Harris M; Faivre-Finn C; Thatcher N; Blackhall F
Lung Cancer; 2011 Sep; 73(3):338-44. PubMed ID: 21296449
[TBL] [Abstract][Full Text] [Related]
15. Double-blind, placebo-controlled, randomized phase 2 study of the proapoptotic agent AT-101 plus docetaxel, in second-line non-small cell lung cancer.
Ready N; Karaseva NA; Orlov SV; Luft AV; Popovych O; Holmlund JT; Wood BA; Leopold L
J Thorac Oncol; 2011 Apr; 6(4):781-5. PubMed ID: 21289522
[TBL] [Abstract][Full Text] [Related]
16. A multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy of paclitaxel-carboplatin alone or with endostar for advanced non-small cell lung cancer.
Han B; Xiu Q; Wang H; Shen J; Gu A; Luo Y; Bai C; Guo S; Liu W; Zhuang Z; Zhang Y; Zhao Y; Jiang L; Zhou J; Jin X
J Thorac Oncol; 2011 Jun; 6(6):1104-9. PubMed ID: 21532504
[TBL] [Abstract][Full Text] [Related]
17. Outcomes in patients with aggressive or refractory disease from REVEL: A randomized phase III study of docetaxel with ramucirumab or placebo for second-line treatment of stage IV non-small-cell lung cancer.
Reck M; Paz-Ares L; Bidoli P; Cappuzzo F; Dakhil S; Moro-Sibilot D; Borghaei H; Johnson M; Jotte R; Pennell NA; Shepherd FA; Tsao A; Thomas M; Carter GC; Chan-Diehl F; Alexandris E; Lee P; Zimmermann A; Sashegyi A; Pérol M
Lung Cancer; 2017 Oct; 112():181-187. PubMed ID: 29191593
[TBL] [Abstract][Full Text] [Related]
18. Aflibercept and Docetaxel versus Docetaxel alone after platinum failure in patients with advanced or metastatic non-small-cell lung cancer: a randomized, controlled phase III trial.
Ramlau R; Gorbunova V; Ciuleanu TE; Novello S; Ozguroglu M; Goksel T; Baldotto C; Bennouna J; Shepherd FA; Le-Guennec S; Rey A; Miller V; Thatcher N; Scagliotti G
J Clin Oncol; 2012 Oct; 30(29):3640-7. PubMed ID: 22965962
[TBL] [Abstract][Full Text] [Related]
19. Docetaxel-carboplatin chemotherapy combined with cetuximab in patients with locally advanced or metastatic non small-cell lung cancer (NSCLC)--results of the nonrandomised phase II study TaxErb.
Fischer JR; Griesinger F; Fink T; Salm T; Marseille A; Wolf M
Lung Cancer; 2012 Mar; 75(3):348-52. PubMed ID: 21908069
[TBL] [Abstract][Full Text] [Related]
20. Phase II study of bevacizumab, cisplatin, and docetaxel plus maintenance bevacizumab as first-line treatment for patients with advanced non-squamous non-small-cell lung cancer combined with exploratory analysis of circulating endothelial cells: Thoracic Oncology Research Group (TORG)1016.
Ikeda S; Kato T; Ogura T; Sekine A; Oda T; Masuda N; Igawa S; Katono K; Otani S; Yamada K; Saito H; Kondo T; Hosomi Y; Nakahara Y; Nishikawa M; Utumi K; Misumi Y; Yamanaka T; Sakamaki K; Okamoto H
BMC Cancer; 2018 Mar; 18(1):241. PubMed ID: 29499653
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
